Early <i>BCR::ABL1</i> Reduction as a Predictor of Deep Molecular Response in Pediatric Chronic-Phase Chronic Myeloid Leukemia.

Patients in the intermediate/high-risk group showed a trend toward poorer long-term outcomes compared with those in the low-risk group (5-year FFS, 53.6% vs. 78.1%; p = 0.095; 5-year EFS, 53.6% vs. 71.3%; p = 0.23).

also in 53,322 other papers